FDA
-
-
-
-
-
-
-
Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investiga
-
-
-
-
-
-
-
Verrica Pharmaceuticals names Chris Chapman chief commercial officer
-
-
-
-
-
-
-
Verrica Pharmaceuticals raises $50 million to retire debt and extend operations
-
-
-
-
-
-
-
Verrica Pharmaceuticals Receives Positive Feedback from the European Medicines Agency (EMA) Supporting a Clear Regulatory Path Forward to File for Approval of YCANTH® in the European Union
-
-
-
-
-
-
-
Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results
-
-
-
-
-
-
-
Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results
-
-
-
-
-
-
-
Verrica Pharmaceuticals Inc. (VRCA) Appoints Noah L. Rosenberg as Chief Medical Officer
-
325,290 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

